B+
Bull case
25%
Probability
Target price
$150.00
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
MNPR
Monopar TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The confirmed rolling NDA submission converts the ALXN1840 thesis from a planned milestone into active regulatory execution. Positive Phase 3 analyses, commercial-readiness work, and reported runway through 2027 provide a credible path to additional value if review and approval progress successfully.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -2.7.
What can break
Analyst coverage, price-reaction attribution, social data, and recent-news breadth are limited.
Momentum
87
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $118.25 · Bull $150.00 · Bear $80.00Analysis 2026-07-27; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-08 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-27 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-08
Investment thesis
As of 2026-09-08
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-08. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $128.50
Why
Momentum87 · Δ7d -0.6
Value41 · Δ7d -0.0
Sentiment68 · Δ7d -2.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -2.7.
Contradictions & invalidation
- • Analyst coverage, price-reaction attribution, social data, and recent-news breadth are limited.
- • Clinical efficacy and safety risks remain despite positive Phase 3 analyses.
- • The stock remains exposed to regulatory delay or rejection, clinical or labeling uncertainty, commercialization risk, and continued operating losses.
Catalyst clock
2026-07-22
Rolling ALXN1840 NDA submission initiated
Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendFlat
Δ7d
-0.6
Δ21d
-9.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
68
62% active weight
Current posture
7d trendSoftening
Δ7d
-2.7
Δ21d
-5.3
Why this grade
Composite grade B. Momentum 87.4 / Value 41.2 / Sentiment 68.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-07-27. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$118.25
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$80.00
Analysis reference price unavailable
Analysis 2026-07-27 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$781.9M
Beta
1.54
Shares Out
6.71M
P/E (TTM) · Derived
-62.9
P/S (TTM)
-
P/FCF (TTM) · Derived
-73.53
Rev YoY
-
EPS YoY
+77.4%
Gross Margin
-
Op Margin
-
Net Debt
-$140.24M
Current Ratio
33.56
As of 2026-09-08 • Updated nightlySource: Internal modelMethods & Data